Celgene (CELG) stock jumped over 30% in the past few trading days — and with good reason. Investors are excited over what is …
In September last year, Celgene (NASDAQ:CELG) bought 750,000 shares of Acceleron Pharma (NASDAQ:XLRN), and for a good reason. Celgene is Acceleron’s largest holder and …
Ardsley fund manager Philip Hempleman has fled out of HMNY, but walked into a new position in CELG, as of the most recent SEC filing.
RBC Capital’s Brian Abrahams believes that the exit of Celgene’s former BD chief is causing an unwarranted dip in the stock; here’s why.
The annual meeting of the American Society of Clinical Oncology (commonly known as ASCO) is around the corner. As usual, abstracts get released …
Oppenheimer’s Leah R. Cann and Canaccord’s John Newman are out with bullish research notes following this biotech giant’s first quarter print.
Cantor’s Mara Goldstein says growth beyond 2020 for CELG just got cloudy with the FDA’s RTF letter for ozanimod.
Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion or $87/share (net of the ~10% it …
Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.
Cantor’s Mara Goldstein is not shaken by the $411 million pretax charge impacting CELG in 4Q, as the stock barely dipped past 1% upon the GED-0301 program cancellation news.